Centauri Therapeutics Ltd.

Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections Investment from the world’s largest venture capital fund focused exclusively on antimicrobial therapeutics and diagnostics extends Series A round to £30M Dr. Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund, appointed to Centauri’s Board of Directors ALDERLEY PARK, England--(BUSINESS WIRE)--Centauri Therapeutics Limited (‘ Centauri ’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6M from AMR Action Fund, extending the Company’s Series A round to £30M. The investment will support the completion of Phase I clinical studies for CTX-187, Centauri’s lead clinical candidate in the ABX-01 programme, and will expand the scope of additional research activities in preparation for Phase II. The funding from AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to investing in urgently needed antimicrobial therapeutics and diagnostics, will support Centauri to advance its lead candidate through a Phase I clinical trial, obtaining key safety data necessary to inform ongoing development. The funds will also enable the Company to carry out further work in preparation for Phase II studies. In addition, Dr. Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund has been appointed to Centauri’s Board of Directors. CTX-187, currently in development ahead of progressing to first in-human clinical trials, was selected as Centauri’s first clinical candidate in 2025 1 . Built on the Company’s proprietary Alphamer ® platform, the compound is a broad-spectrum antimicrobial designed to treat clinically prevalent and multidrug-resistant Gram-negative bacteria, expanding therapeutic options for vulnerable patients. It features a dual mechanism-of-action that combines immunotherapeutic effects through complement activation and opsonophagocytosis with intrinsic antibacterial activity. Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics, said: “ We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support.” Dr. Henry Skinner, Chief Executive Officer, AMR Action Fund, commented: “The growing burden of drug-resistant Gram-negative infections is one of the most pressing challenges in global health, leaving patients with limited and increasingly ineffective treatment options. Centauri’s approach represents a promising opportunity to address this challenge, and we are pleased to support the team as they advance toward first-in-human studies.” Centauri closed a £24M Series A round in January 2022, with investment from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund. The Company has also been supported by CARB-X 2 (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to undertake research and development studies since 2019, advancing the ABX-01 programme from Lead Optimization to the Preclinical phase. In 2024, Centauri was selected to receive a grant under the first round of PACE-AMR funding. Press Release (4 th March, 2025): Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), Germany’s Federal Ministry of Research, Technology and Space (BMFTR), and the Novo Nordisk Foundation. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders . Contacts Media Katie Odgaard katie.odgaard@zymecommunications.com

ALDERLEY PARK, England--(BUSINESS WIRE)--Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri’s ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X’s total support from 2019 to date to $12.3M. Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 20251. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company’s proprietary Alphamer® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound’s activity against Gram-negative bacteria. “The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies,” said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. “We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients.” Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: “We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials.” CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.

LONDON--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug candidate will now be further developed ahead of progression to first in-human clinical studies. The lead candidate in the ABX-01 programme is a broad-spectrum antimicrobial peptide specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Preclinical studies have demonstrated the compound’s activity against Gram-negative bacteria. “We are excited to enter the clinical development phase with the ABX-01 lead candidate, thanks to our dedicated team who have worked hard to advance our Alphamer platform to this crucial stage. The platform has the potential to address a vital gap in the current anti-infective treatment landscape, and we remain confident that our lead candidate will continue to demonstrate this as we progress towards a Phase I clinical trial,” commented Dr Jennifer Schneider, CEO, Centauri Therapeutics. “We are proud to progress this molecule with the continuous support of our investors and our long-standing partner, CARB-X, for which we are grateful.” Dr Helen Bright, CSO, Centauri Therapeutics, said: "Our focus at Centauri Therapeutics has always been on developing novel immune therapy approaches to expand treatment options for the most vulnerable, starting with the anti-infectives space. Reaching this stage highlights the potential of our disruptive technology, not only in anti-infectives, but also within the oncology and vaccines spaces. I look forward to working alongside our brilliant and highly motivated team to take us into this next phase of development." Centauri is now conducting regulatory preclinical activities to enable streamlined progression of its lead clinical candidate into a Phase I clinical trial. Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.